Skip to main content
Erschienen in: Metabolic Brain Disease 6/2016

28.04.2016 | Original Article

Probiotics in management of hepatic encephalopathy

verfasst von: Barjesh Chander Sharma, Jatinderpal Singh

Erschienen in: Metabolic Brain Disease | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Gut microflora leads to production of ammonia and endotoxins which play important role in the pathogenesis of hepatic encephalopathy (HE). There is relationship between HE and absorption of nitrogenous substances from the intestines. Probiotics play a role in treatment of HE by causing alterations in gut flora by decreasing the counts of pathogen bacteria, intestinal mucosal acidification, decrease in production and absorption of ammonia, alterations in permeability of gut, decreased endotoxin levels and changes in production of short chain fatty acids. Role of gut microbiota using prebiotics, probiotics and synbiotics have been evaluated in the management of minimal hepatic encephalopathy (MHE), overt HE and prevention of HE. Many studies have shown efficacy of probiotics in reduction of blood ammonia levels, treatment of MHE and prevention of HE. However these trials have problems like inclusion of small number of patients, short treatment durations, variability in HE/MHE related outcomes utilized and high bias risk, errors of systematic and random types. Systematic reviews also have shown different results with one systematic review showing clinical benefits whereas another concluded that probiotics do not have any role in treatment of MHE or HE. Also practical questions on optimal dose, ideal combination of organisms, and duration of treatment and persistence of benefits on long term follow-up are still to be clarified. At present, there are no recommendations for use of probiotics in patients with HE.
Literatur
Zurück zum Zitat Agrawal A, Sharma BC, Sharma P, Sarin SK (2012) Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label randomized controlled trial of lactulose, probiotics and no therapy. Am J Gastroenterol 107:1043–1050CrossRefPubMed Agrawal A, Sharma BC, Sharma P, Sarin SK (2012) Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label randomized controlled trial of lactulose, probiotics and no therapy. Am J Gastroenterol 107:1043–1050CrossRefPubMed
Zurück zum Zitat Amodio P, Bemeur C, Butterworth R, Cordoba J, Kato A, Montagnese S, Uribe M, Vilstrup H, Morgan MY (2013) The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. Heoatology 58:325–336 Amodio P, Bemeur C, Butterworth R, Cordoba J, Kato A, Montagnese S, Uribe M, Vilstrup H, Morgan MY (2013) The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. Heoatology 58:325–336
Zurück zum Zitat Bajaj JS (2014) The role of microbiota in hepatic encephalopathy. Gut Microbes 5:1–7CrossRef Bajaj JS (2014) The role of microbiota in hepatic encephalopathy. Gut Microbes 5:1–7CrossRef
Zurück zum Zitat Bajaj JS, Saeian K, Christensen KM, Hafeezullah M, Varma RR, Franco J, Pleuss JA, Krakower G, Hoffmann RG, Binion DG (2008) Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol 103:1707–1715CrossRefPubMed Bajaj JS, Saeian K, Christensen KM, Hafeezullah M, Varma RR, Franco J, Pleuss JA, Krakower G, Hoffmann RG, Binion DG (2008) Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol 103:1707–1715CrossRefPubMed
Zurück zum Zitat Bajaj JS, Ridlon JM, Hylemon PB, Thacker LR, Heuman DM, Smith S, Sikaroodi M, Gillevet PM (2012) Linkage of gut microbiome with cognition in hepatic encephalopathy. Am J PhysiolGastrointest Liver Physiol 302:G168–G175CrossRef Bajaj JS, Ridlon JM, Hylemon PB, Thacker LR, Heuman DM, Smith S, Sikaroodi M, Gillevet PM (2012) Linkage of gut microbiome with cognition in hepatic encephalopathy. Am J PhysiolGastrointest Liver Physiol 302:G168–G175CrossRef
Zurück zum Zitat Bauer TM, Schwacha H, Steinbrückner B, Brinkmann FE, Ditzen AK, Aponte JJ, Pelz K, Berger D, Kist M, Blum HE (2001) Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia. Am J Gastroenterol 96:2962–2967CrossRefPubMed Bauer TM, Schwacha H, Steinbrückner B, Brinkmann FE, Ditzen AK, Aponte JJ, Pelz K, Berger D, Kist M, Blum HE (2001) Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia. Am J Gastroenterol 96:2962–2967CrossRefPubMed
Zurück zum Zitat Bauer TM, Schwacha H, Steinbrückner B, Brinkmann FE, Ditzen AK, Aponte JJ, Pelz K, Berger D, Kist M, Blum HE (2002) Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia. Am J Gastroenterol 97:2364–2370CrossRefPubMed Bauer TM, Schwacha H, Steinbrückner B, Brinkmann FE, Ditzen AK, Aponte JJ, Pelz K, Berger D, Kist M, Blum HE (2002) Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia. Am J Gastroenterol 97:2364–2370CrossRefPubMed
Zurück zum Zitat Chen Y, Yang F, Lu H, Wang B, Chen Y, Lei D, Wang Y, Zhu B, Li L (2011) Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology 54:562–572CrossRefPubMed Chen Y, Yang F, Lu H, Wang B, Chen Y, Lei D, Wang Y, Zhu B, Li L (2011) Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology 54:562–572CrossRefPubMed
Zurück zum Zitat Chiva M, Soriano G, Rochat I, Peralta C, Rochat F, Llovet T, Mirelis B, Schiffrin EJ, Guarner C, Balanzó J (2002) Effect of lactobacillus johnsonii La1 and antioxidants on intestinal flora and bacterial translocation in rats with experimental cirrhosis. J Hepatol 37:456–462CrossRefPubMed Chiva M, Soriano G, Rochat I, Peralta C, Rochat F, Llovet T, Mirelis B, Schiffrin EJ, Guarner C, Balanzó J (2002) Effect of lactobacillus johnsonii La1 and antioxidants on intestinal flora and bacterial translocation in rats with experimental cirrhosis. J Hepatol 37:456–462CrossRefPubMed
Zurück zum Zitat Dhiman RK, Rana B, Agrawal S, Garg A, Chopra M, Thumburu KK, Khattri A, Malhotra S, Duseja A, Chawla YK (2014) Probiotics VSL #3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized controlled trial. Gastroenterology 147:1327–1337CrossRefPubMed Dhiman RK, Rana B, Agrawal S, Garg A, Chopra M, Thumburu KK, Khattri A, Malhotra S, Duseja A, Chawla YK (2014) Probiotics VSL #3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized controlled trial. Gastroenterology 147:1327–1337CrossRefPubMed
Zurück zum Zitat Ding X, Zhang F, Wang Y (2014) Probiotics vs. lactulose for minimal hepatic encephalopathy therapy. Aliment Pharmacol Ther 39:1000–1001CrossRefPubMed Ding X, Zhang F, Wang Y (2014) Probiotics vs. lactulose for minimal hepatic encephalopathy therapy. Aliment Pharmacol Ther 39:1000–1001CrossRefPubMed
Zurück zum Zitat Gupta A, Dhiman RK, Kumari S, Rana S, Agarwal R, Duseja A, Chawla Y (2010) Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. J Hepatol 53:849–855CrossRefPubMed Gupta A, Dhiman RK, Kumari S, Rana S, Agarwal R, Duseja A, Chawla Y (2010) Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. J Hepatol 53:849–855CrossRefPubMed
Zurück zum Zitat Holte K, Krag A, Gluud LL (2012) Systematic review and meta-analysis of randomized trials on probiotics for hepatic encephalopathy. Hepatol Res 42:1008–1015CrossRefPubMed Holte K, Krag A, Gluud LL (2012) Systematic review and meta-analysis of randomized trials on probiotics for hepatic encephalopathy. Hepatol Res 42:1008–1015CrossRefPubMed
Zurück zum Zitat Jia L, Zhang MH (2005) Comparison of probiotics and lactulose in the treatment of minimal hepatic encephalopathy in rats. World J Gastroenterol 11:908–911CrossRefPubMedPubMedCentral Jia L, Zhang MH (2005) Comparison of probiotics and lactulose in the treatment of minimal hepatic encephalopathy in rats. World J Gastroenterol 11:908–911CrossRefPubMedPubMedCentral
Zurück zum Zitat Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM (2004) Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 39:1441–1449CrossRefPubMed Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM (2004) Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 39:1441–1449CrossRefPubMed
Zurück zum Zitat Loguercio C, Del Vecchio BC, Coltorti M (1987) Enterococcus lactic acid bacteria strain SF68 and lactulose in hepatic encephalopathy: a controlled study. J Int Med Res 15:335–343PubMed Loguercio C, Del Vecchio BC, Coltorti M (1987) Enterococcus lactic acid bacteria strain SF68 and lactulose in hepatic encephalopathy: a controlled study. J Int Med Res 15:335–343PubMed
Zurück zum Zitat Loguercio C, Abbiati R, Rinaldi M, Romano A, Del Vecchio BC, Coltorti M (1995) Long-term effects of enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. J Hepatol 23:39–46CrossRefPubMed Loguercio C, Abbiati R, Rinaldi M, Romano A, Del Vecchio BC, Coltorti M (1995) Long-term effects of enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. J Hepatol 23:39–46CrossRefPubMed
Zurück zum Zitat Lunia MK, Sharma BC, Sachdeva S (2013) Small intestinal bacterial overgrowth and delayed orocecal transit time in patients with cirrhosis and low-grade hepatic encephalopathy. Hepatol Int 7:268–273CrossRefPubMed Lunia MK, Sharma BC, Sachdeva S (2013) Small intestinal bacterial overgrowth and delayed orocecal transit time in patients with cirrhosis and low-grade hepatic encephalopathy. Hepatol Int 7:268–273CrossRefPubMed
Zurück zum Zitat Lunia MK, Sharma BC, Sharma P, Sachdeva S, Srivastava S (2014) Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial. Clin Gastroenterol Hepatol 12:1003–1008CrossRefPubMed Lunia MK, Sharma BC, Sharma P, Sachdeva S, Srivastava S (2014) Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial. Clin Gastroenterol Hepatol 12:1003–1008CrossRefPubMed
Zurück zum Zitat Malaguarnera M, Greco F, Barone G, Gargante MP, Toscano MA (2007) Bifidobacte-riumlongumwithfructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Dig Dis Sci 52:3259–3265CrossRefPubMed Malaguarnera M, Greco F, Barone G, Gargante MP, Toscano MA (2007) Bifidobacte-riumlongumwithfructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Dig Dis Sci 52:3259–3265CrossRefPubMed
Zurück zum Zitat Malaguarnera M, Gargante MP, Malaguarnera G, Salmeri M, Mastrojeni S, Rampello L, Pennisi G, Li Volti G, Galvano F (2010) Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy. Eur J Gastroenterol Hepatol 22:199–206CrossRefPubMed Malaguarnera M, Gargante MP, Malaguarnera G, Salmeri M, Mastrojeni S, Rampello L, Pennisi G, Li Volti G, Galvano F (2010) Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy. Eur J Gastroenterol Hepatol 22:199–206CrossRefPubMed
Zurück zum Zitat McGee RG, Bakens A, Wiley K, Riordan SM, Webster AC (2011) Probiotics for patients with hepatic encephalopathy. Cochrane Database Syst Rev 9(11):CD008716 McGee RG, Bakens A, Wiley K, Riordan SM, Webster AC (2011) Probiotics for patients with hepatic encephalopathy. Cochrane Database Syst Rev 9(11):CD008716
Zurück zum Zitat Mittal VV, Sharma BC, Sharma P, Sarin SK (2011) A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol 23:725–732CrossRefPubMed Mittal VV, Sharma BC, Sharma P, Sarin SK (2011) A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol 23:725–732CrossRefPubMed
Zurück zum Zitat Mouli VP, Benjamin J, Singh MB, Mani K, Garg SK, Saraya A (2014) Effects of probiotic VSL#3 in the treatment of minimal hepatic encephalopathy: A non-inferiority randomized controlled trial. Hepatol Res. doi:10.11111/hepr12429 Mouli VP, Benjamin J, Singh MB, Mani K, Garg SK, Saraya A (2014) Effects of probiotic VSL#3 in the treatment of minimal hepatic encephalopathy: A non-inferiority randomized controlled trial. Hepatol Res. doi:10.​11111/​hepr12429
Zurück zum Zitat Pereg D, Kotliroff A, Gadoth N, Hadary R, Lishner M, Kitay-Cohen Y (2011) Probiotics for patients with compensated liver cirrhosis: a double-blind placebo-controlled study. Nutrition 27:177–181CrossRefPubMed Pereg D, Kotliroff A, Gadoth N, Hadary R, Lishner M, Kitay-Cohen Y (2011) Probiotics for patients with compensated liver cirrhosis: a double-blind placebo-controlled study. Nutrition 27:177–181CrossRefPubMed
Zurück zum Zitat Saji S, Kumar S, Thomas V (2011) A randomized double blind placebo controlled trial of probiotics in minimal hepatic encephalopathy. Trop Gastroenterol 32:128–132PubMed Saji S, Kumar S, Thomas V (2011) A randomized double blind placebo controlled trial of probiotics in minimal hepatic encephalopathy. Trop Gastroenterol 32:128–132PubMed
Zurück zum Zitat Sharma P, Sharma BC, Puri V, Sarin SK (2008) An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol 20:506–511CrossRefPubMed Sharma P, Sharma BC, Puri V, Sarin SK (2008) An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol 20:506–511CrossRefPubMed
Zurück zum Zitat Shukla S, Shukla A, Mehboob S, Guha S (2011) Meta-analysis: the effects of gut flora modulation using prebiotics, probiotics and synbiotics on minimal hepatic encephalopathy. Aliment PharmacolTher 33:662–671CrossRef Shukla S, Shukla A, Mehboob S, Guha S (2011) Meta-analysis: the effects of gut flora modulation using prebiotics, probiotics and synbiotics on minimal hepatic encephalopathy. Aliment PharmacolTher 33:662–671CrossRef
Zurück zum Zitat Wiest R, Chen F, Cadelina G, Groszmann RJ, Garcia-Tsao G (2003) Effect of lactobacillus-fermented diets on bacterial translocation and intestinal flora in experimental prehepatic portal hypertension. Dig Dis Sci 48:1136–1141CrossRefPubMed Wiest R, Chen F, Cadelina G, Groszmann RJ, Garcia-Tsao G (2003) Effect of lactobacillus-fermented diets on bacterial translocation and intestinal flora in experimental prehepatic portal hypertension. Dig Dis Sci 48:1136–1141CrossRefPubMed
Zurück zum Zitat Xu J, Ma R, Chen LF, ZhaoLJ CK, Zhang RB (2014) Effects of probiotic therapy on hepatic encephalopathy in patients with liver cirrhosis: an updated meta-analysis of six randomized controlled trials. Hepatobiliary Pancreat Dis Int 13:354–360CrossRefPubMed Xu J, Ma R, Chen LF, ZhaoLJ CK, Zhang RB (2014) Effects of probiotic therapy on hepatic encephalopathy in patients with liver cirrhosis: an updated meta-analysis of six randomized controlled trials. Hepatobiliary Pancreat Dis Int 13:354–360CrossRefPubMed
Zurück zum Zitat Zhang Z, Zhai H, Geng J, Yu R, Ren H, Fan H, Shi P (2013) Large-scale survey of gut microbiota associated with MHE via 16S rRNA-based pyrosequencing. Am J Gastroenterol 108:1601–1611CrossRefPubMed Zhang Z, Zhai H, Geng J, Yu R, Ren H, Fan H, Shi P (2013) Large-scale survey of gut microbiota associated with MHE via 16S rRNA-based pyrosequencing. Am J Gastroenterol 108:1601–1611CrossRefPubMed
Zurück zum Zitat Ziada DH, Soliman HH, El Yamani SA, Hamisa MF, Hasan AM (2013) Can lactobacillus acidophilus improve minimal hepatic encephalopathy? A neurometabolite study using magnetic resonance spectroscopy. Arab Journal of Gastroenterology 14:116–122CrossRefPubMed Ziada DH, Soliman HH, El Yamani SA, Hamisa MF, Hasan AM (2013) Can lactobacillus acidophilus improve minimal hepatic encephalopathy? A neurometabolite study using magnetic resonance spectroscopy. Arab Journal of Gastroenterology 14:116–122CrossRefPubMed
Metadaten
Titel
Probiotics in management of hepatic encephalopathy
verfasst von
Barjesh Chander Sharma
Jatinderpal Singh
Publikationsdatum
28.04.2016
Verlag
Springer US
Erschienen in
Metabolic Brain Disease / Ausgabe 6/2016
Print ISSN: 0885-7490
Elektronische ISSN: 1573-7365
DOI
https://doi.org/10.1007/s11011-016-9826-x

Weitere Artikel der Ausgabe 6/2016

Metabolic Brain Disease 6/2016 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.